Individualized chemotherapy in advanced NSCLC patients based on mRNA levels of BRCA1 and RRM1

[1]  Jie Luo,et al.  Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer , 2011, Medical oncology.

[2]  J Zhang,et al.  ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer , 2011, Medical oncology.

[3]  Wanqing Chen,et al.  Attributable causes of lung cancer incidence and mortality in China , 2011, Thoracic cancer.

[4]  Wanqing Chen,et al.  Cancer incidence and mortality in China, 2006 , 2011, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[5]  Yasunori Sato,et al.  Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  H. Bai,et al.  High expression of ERCC1 is a poor prognostic factor in Chinese patients with non-small cell lung cancer receiving cisplatin-based therapy , 2010 .

[7]  J Zhang,et al.  High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients , 2010, Cancer investigation.

[8]  C. Zhou,et al.  ERCC1, RRM1, and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. , 2010 .

[9]  Wanqing Chen,et al.  [An analysis of lung cancer mortality in China, 2004 - 2005]. , 2010, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine].

[10]  Young Hak Kim,et al.  Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. , 2009, Lung cancer.

[11]  J. Sørensen,et al.  Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. , 2009, Lung cancer.

[12]  Young Hak Kim,et al.  Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. , 2009, Lung cancer.

[13]  D. Mavroudis,et al.  Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients , 2008, PloS one.

[14]  R. Rosell,et al.  BRCA1: a new genomic marker for non-small-cell lung cancer. , 2008, Clinical lung cancer.

[15]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Jassem,et al.  BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer , 2007, PloS one.

[17]  Y. Maehara,et al.  Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non‐small cell lung cancer , 2007, International journal of cancer.

[18]  D. Gandara,et al.  Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Alan Cantor,et al.  Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Ardizzoni,et al.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. , 2007, Journal of the National Cancer Institute.

[21]  R. Rosell,et al.  Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. , 2007, Clinical lung cancer.

[22]  Zhong Zheng,et al.  DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. , 2007, The New England journal of medicine.

[23]  M. Taron,et al.  Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  G. Bepler,et al.  Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.

[25]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[26]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[27]  I. Thompson,et al.  Cancer Incidence and Mortality , 2013 .

[28]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.